Logo

Servier and MiNA Therapeutics Collaborate to Develop saRNA Therapies for Neurological Diseases

Share this

Servier and MiNA Therapeutics Collaborate to Develop saRNA Therapies for Neurological Diseases

Shots:

  • MiNA to receive $267.6M in up front- exclusivity fee on first neurological target and will be eligible to receive research- development- regulatory and commercial milestones along with royalties
  • Servier will lead pre/ clinical development of lead candidates and will have the rights to commercialize any products that emerges from the collaboration
  • The collaboration integrates Servier’s CNS expertise and MiNA’s small activating RNA technology to identify new potential treatments for restoring normal cell function in neurological disorders

 ­ Ref: Businesswire| Image: Nohat

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions